Phase 3 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to give written consent to participate in the study.
• People aged 18 to 80 years old, of any gender.
• People with a general health performance level that is either fully active, restricted in strenuous activity but able to do light work, or able to care for themselves but unable to carry out any work (confirm with trial site for exact rating).
• People who have been diagnosed with a specific type of T-cell lymphoma confirmed by tissue testing, including angioimmunoblastic T-cell lymphoma, follicular helper T-cell lymphoma (follicular type), or follicular helper T-cell lymphoma (not otherwise specified).
• People who have at least one area of lymphoma that can be measured using standard imaging criteria (Lugano 2014 Classification).
• People whose blood test results meet minimum thresholds for red blood cells, white blood cells, and platelets, and whose kidney and liver function tests fall within acceptable ranges (confirm specific values with trial site).
• People whose doctors estimate they are expected to live for at least 6 months.

Who may not be able to join:

• People whose lymphoma has spread to the brain or spinal cord.
• People who have already received any treatment aimed at their lymphoma.
• People for whom a stem cell transplant (either from themselves or a donor) is already planned after achieving remission.
• People who have had another cancer in the past 5 years, unless it was a localised cancer that has been fully cured.
• People who have previously been treated with chemotherapy drugs for a non-cancer condition, such as rheumatoid arthritis.
• People who have taken part in another clinical trial or received an experimental treatment within the past 3 months.
• People who have a medical reason they cannot receive any component of the CHOP chemotherapy regimen.
• People who are taking high-dose steroid medication (above 30 mg per day of prednisone or equivalent) for reasons unrelated to controlling lymphoma symptoms, or who do not meet the specific steroid dose stability requirements (confirm details with trial site).
• People with serious ongoing brain or nervous system disease, such as a condition called progressive multifocal leukoencephalopathy, or significant nerve damage.
• People with serious or uncontrolled heart problems, including moderate-to-severe heart failure, recent heart attack or unstable chest pain (within 6 months), abnormal heart rhythms requiring treatment, low heart pumping function, certain inherited or structural heart muscle diseases, a history of abnormal heart electrical readings, symptomatic coronary heart disease, or other heart conditions the doctors consider unsuitable.
• People who have a history of scarring or inflammation of the lungs (interstitial lung disease), or who currently show signs of this on imaging scans.
• People who have difficulty swallowing, ongoing serious diarrhoea, bowel obstruction, or who have had their stomach surgically removed, as these may affect how oral medication is absorbed.
• People with a history of blood clots in the deep veins or lungs.
• People who have had active bleeding within the past 2 months, are currently taking blood-thinning medication, or show signs of potential bleeding risk such as swollen veins in the oesophagus, active stomach ulcers, or a positive test for blood in the stool (unless bleeding was caused by the lymphoma itself, which doctors will assess individually).
• People who have had major surgery such as brain, chest, or abdominal surgery within the past 4 weeks, or any minor surgical procedure within the past 7 days, or who have serious unhealed wounds, ulcers, or fractures.
• People who have had an active infection requiring antibiotic or antiviral treatment by mouth or through a drip within the 2 weeks before starting the trial (people taking preventive antibiotics may still be eligible).
• People with certain active viral infections, including active hepatitis B, active hepatitis C, or active syphilis (confirm specific testing criteria with trial site).
• People with a history of HIV infection, other immune deficiency conditions, or who have previously had an organ or stem cell transplant.
• People with a mental health condition or cognitive difficulty that would prevent them from fully understanding the consent process or following the study requirements.
• People with current drug or alcohol dependency.
• Women who are able to become pregnant and are unwilling or unable to use effective contraception throughout the treatment period and for 12 weeks after the last dose; this also applies to the partners of male participants.
• People who have any other condition the trial doctors consider unsuitable for participation.

Important: Always verify eligibility with the trial site directly before applying.